{
    "organizations": [],
    "uuid": "d62d462fabf4105a4ebfd2730f03ba134fc4ffde",
    "author": "",
    "url": "https://www.reuters.com/article/brief-reata-announces-positive-top-line/brief-reata-announces-positive-top-line-data-for-treatment-of-ph-ild-with-bardoxolone-methyl-from-phase-2-lariat-trial-idUSASC09TB7",
    "ord_in_thread": 0,
    "title": "BRIEF-Reata Announces Positive Top-Line Data For Treatment Of PH-ILD With Bardoxolone Methyl From Phase 2 Lariat Trial",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 22, 2018 / 12:08 PM / Updated 11 minutes ago BRIEF-Reata Announces Positive Top-Line Data For Treatment Of PH-ILD With Bardoxolone Methyl From Phase 2 Lariat Trial Reuters Staff 1 Min Read March 22 (Reuters) - Reata Pharmaceuticals Inc: * REATA ANNOUNCES POSITIVE TOP-LINE DATA FOR TREATMENT OF PH-ILD WITH BARDOXOLONE METHYL FROM THE PHASE 2 LARIAT TRIAL * REATA PHARMACEUTICALS INC - RESULTS FROM PHASE 2 LARIAT TRIAL SHOWED SIGNIFICANT IMPROVEMENTS IN PRIMARY ENDPOINT * REATA PHARMACEUTICALS INC - NO SAFETY SIGNALS WERE IDENTIFIED IN TRIAL Source text for Eikon: Further company coverage:",
    "published": "2018-03-22T14:07:00.000+02:00",
    "crawled": "2018-03-22T14:23:14.053+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "pm",
        "updated",
        "minute",
        "ago",
        "announces",
        "positive",
        "data",
        "treatment",
        "bardoxolone",
        "methyl",
        "phase",
        "lariat",
        "trial",
        "reuters",
        "staff",
        "min",
        "read",
        "march",
        "reuters",
        "reata",
        "pharmaceutical",
        "inc",
        "reata",
        "announces",
        "positive",
        "data",
        "treatment",
        "bardoxolone",
        "methyl",
        "phase",
        "lariat",
        "trial",
        "reata",
        "pharmaceutical",
        "inc",
        "result",
        "phase",
        "lariat",
        "trial",
        "showed",
        "significant",
        "improvement",
        "primary",
        "endpoint",
        "reata",
        "pharmaceutical",
        "inc",
        "safety",
        "signal",
        "identified",
        "trial",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}